Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BeOne Medicines Ltd ( (HK:6160) ) just unveiled an update.
BeOne Medicines Ltd. has issued an overseas regulatory announcement in Hong Kong to notify investors of the internet availability of its proxy materials, which have also been filed with the U.S. Securities and Exchange Commission as definitive additional proxy materials under Schedule 14A. The move underscores the company’s compliance with dual listing and disclosure obligations across Hong Kong and U.S. markets, aiming to provide shareholders with transparent access to governance-related documents ahead of forthcoming corporate actions.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page.
More about BeOne Medicines Ltd
BeOne Medicines Ltd. is a Switzerland-incorporated pharmaceutical company listed on the Hong Kong Stock Exchange. The company’s board is chaired by executive director John V. Oyler and includes a mix of non-executive and independent non-executive directors with extensive experience in global biopharmaceuticals.
Average Trading Volume: 3,809,861
Technical Sentiment Signal: Buy
Current Market Cap: HK$269B
Learn more about 6160 stock on TipRanks’ Stock Analysis page.